1. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
- Author
-
Kawashiri SY, Kawakami A, Ueki Y, Imazato T, Iwamoto N, Fujikawa K, Aramaki T, Tamai M, Nakamura H, Origuchi T, Ida H, and Eguchi K
- Subjects
- Antirheumatic Agents administration & dosage, Blood Sedimentation, C-Reactive Protein analysis, Cartilage Oligomeric Matrix Protein, Etanercept, Female, Humans, Immunoglobulin G administration & dosage, Matrilin Proteins, Matrix Metalloproteinase 3 blood, Middle Aged, Prospective Studies, Receptors, Tumor Necrosis Factor administration & dosage, Remission Induction, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid blood, Extracellular Matrix Proteins blood, Glycoproteins blood, Immunoglobulin G therapeutic use, Receptors, Tumor Necrosis Factor therapeutic use
- Abstract
Objective: The aim of this study was to evaluate whether serum COMP can estimate the therapeutic response of RA after 6 months of treatment with etanercept., Methods: Forty-five RA patients receiving 25 mg of etanercept twice a week for 6 months were registered in this prospective observational study. Clinical response to the therapy was evaluated by DAS 28. Laboratory variables- COMP, CRP, ESR, IgM-RF, MMP-3, and anti-CCP Ab -were assessed at baseline and after 6 months of treatment. We assessed the correlations between serum COMP and other variables and whether serum COMP is associated with DAS28 remission., Results: Serum COMP correlated with DAS28-ESR (p < 0.05, r = 0.40) at baseline. At 6 months of etanercept treatment, 10 patients entered remission (DAS28-ESR < 2.6) whereas the other 35 patients did not (DAS28-ESR > 2.6). The decrement of serum COMP at 6 months was significant in the remission group (N = 10) but not in the non-remission group (N = 35). On the other hand, CRP, ESR and MMP-3 decreased at 6 months regardless of remission status. IgM-RF titer as well as anti-CCP Ab titer did not differ at 6 months., Conclusions: Serum COMP at baseline reflects clinical disease activity of RA. Serum COMP is a valuable serologic marker to identify the subset of RA patients achieving remission during treatment with etanercept., (Copyright © 2010. Published by Elsevier SAS.)
- Published
- 2010
- Full Text
- View/download PDF